Calypte Biomedical Completes First Sale Of Aware(TM) HIV-1/2 OMT Rapid Oral Fluid Test In India
Roger I. Gale, Calypte's President and Chief Executive Officer, stated, "This sale marks a major milestone for us both as our first sale in India and as our entry into the Indian governmental market. Our Aware™ oral fluid test is ideally suited for large institutions such as India's paramilitary forces which need to protect the welfare of their workforces." Mr. Gale continued, "We applaud the Government of India's ambitious plans to combat HIV/AIDS. We believe that the safety and ease of use of non-invasive tests such as our Aware™ HIV-1/2 OMT will be instrumental in containing costs and improving efficiencies as India scales up its testing initiatives. Calypte's Aware™ HIV-1/2 OMT test is the first and currently only oral fluid test approved in India."
Sujata Mital, Director of Sumit Biosciences Pvt. Ltd., Calypte's distributor in India, stated, "India's paramilitary forces have a vested interest in guarding the health and welfare of their personnel. These personnel are highly trained and make important contributions to guarding India's security. Non-invasive testing will help India's paramilitary organizations safeguard their commitment to and investment in human capital. Further, the experience with non-invasive testing gained by these organizations will concretely demonstrate the advantages of oral fluid testing."
About India's HIV Program
India recently embarked on its Third National AIDS Control Program (NACP-III) with the overall goal of halting and reversing its HIV/AIDS epidemic. Since India's reported prevalence rate remains well below 1%, the major focus of NACP-III will be on scaling up prevention and control initiatives. According to The World Bank Project Appraisal Document on NACP-III, India; dated March 22, 2007, of the US $2.6 billion budgeted over five years for NACP-III, over US $1.8 billion has been allocated to scaling up prevention efforts. One of the major goals cited for NACP-III is increasing the number of people tested from 3 million in 2006 to 22 million by 2011.
About Calypte Biomedical
Calypte Biomedical Corporation is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware™ HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability.
The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent filings with the SEC.
Calypte Biomedical Corporation
Calypte biomedicale finalizat prima vânzare de conºtient (tm) de HIV-1 / 2 OMT test rapid de lichide pe cale oralã în India - Calypte Biomedical Completes First Sale Of Aware(TM) HIV-1/2 OMT Rapid Oral Fluid Test In India - articole medicale engleza - startsanatate